We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    oxytocin frontotemporal dementia

Intranasal Oxytocin for Frontotemporal Dementia (FOXY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03260920
Recruitment Status : Recruiting
First Posted : August 24, 2017
Last Update Posted : January 17, 2023
Weston Brain Institute
Canadian Institutes of Health Research (CIHR)
Berry Consultants
Information provided by (Responsible Party):
Lawson Health Research Institute

Brief Summary:
The purpose of this study is to assess the safety, tolerability and effects on behaviour of Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive saline substance that contains no medication) in participants with frontotemporal dementia/Pick's disease. This study will take place in approximately 15 centres across Canada and the United States. Approximately 112 patients in total will be enrolled in this study. In the first phase we will examine which of three different dosing schedules of oxytocin may be more effective. In the second phase of the study, patients entering the study will be randomized to the oxytocin dosing schedule that appeared most effective in the first phase.

Condition or disease Intervention/treatment Phase
Frontotemporal Dementia Drug: Syntocinon Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: A Proof-of-Concept Double Blind Randomized Controlled, Cross-Over Adaptive Design Trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double Blind
Primary Purpose: Treatment
Official Title: A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
Actual Study Start Date : January 31, 2018
Estimated Primary Completion Date : January 31, 2023
Estimated Study Completion Date : December 31, 2023

Arm Intervention/treatment
Experimental: Low Dose Drug: Syntocinon
Intranasal Oxytocin
Other Name: Intranasal Oxytocin

Experimental: Medium Dose Drug: Syntocinon
Intranasal Oxytocin
Other Name: Intranasal Oxytocin

Experimental: High Dose Drug: Syntocinon
Intranasal Oxytocin
Other Name: Intranasal Oxytocin

Primary Outcome Measures :
  1. Change in Neuropsychiatric Inventory (NPI) apathy/indifference domain score [ Time Frame: Up to 20 weeks ]
    Pilot data from our two prior studies of oxytocin in FTD have driven the selection of the NPI as the primary outcome measure.

Secondary Outcome Measures :
  1. Change in emotional facial expression recognition performance [ Time Frame: Up to 20 weeks ]
  2. Change in the Revised Self-Monitoring Scale score [ Time Frame: Up to 20 weeks ]
  3. Change in modified Clinicians Global Impression of Change (apathy) scores [ Time Frame: Up to 20 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of probable FTD (behavioural variant FTD, FTD-semantic subtype or FTD-Progressive Nonfluent Aphasia) with supportive brain imaging (centrally rated frontotemporal atrophy score of 2 or greater on brain MRI or CT) or known FTD causing genetic mutation.68
  • Current symptoms of social apathy/indifference as measured by NPI apathy/indifference severity subscale score >= 2 indicating the presence of moderate to marked levels of apathy/indifference.
  • Study partner who consents to study participation and who cares for/visits the patient daily for at least 3 hours/day and who can administer all trial medications.
  • FTLD-CDR score 0-2.
  • MMSE >10.
  • Stable baseline medications related to cognition or behaviour for >=30 days such as acetylcholinesterase inhibitors, memantine, anti-depressants, antipsychotic agents, other mood stabilizers, benzodiazepines.
  • Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from their substitute decision maker).

Exclusion Criteria:

  • History of stroke, other neurologic or psychiatric disorder other than FTD that is considered to better account for behavioural symptoms.
  • History of a myocardial infarction within the last two years or congestive heart failure.
  • Current uncontrolled hypertension
  • Current bradycardia (rate < 50 beats per minute/bpm) or tachycardia (rate > 100 bpm)
  • Current hyponatremia (Na <135 mEq/L)
  • Current use of topical prostaglandin medications applied to the cervix.
  • Females who are pregnant or breastfeeding, or planning to conceive within the study period.
  • Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug, whichever is longer.
  • Participant has speech difficulties that in the opinion of the investigator would be incompatible with neuropsychology and safety assessments
  • History of cancer except:

    • If considered to be cured
    • If not being actively treated with anti-cancer therapy or radiotherapy and, in the opinion of the investigator, not likely to require treatment in the ensuing 5 years
    • For prostate cancer or basal cell carcinoma, no significant progression over the previous 2 years
  • Any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.
  • For the CSF sub-study, current use of anticoagulant medications (warfarin, rivaroxaban, etc.).
  • Plan for FTD patient to be placed into long-term care or plan for hospital admission for any kind of treatment within study period or if caregiver plans for holidays/respite care > 3 days during study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03260920

Layout table for location information
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90095
Contact: Diana Chavez    310-478-3711 ext 48176    dianachavez@mednet.ucla.edu   
Principal Investigator: Mario Mendez, MD         
University of California, San Francisco Recruiting
San Francisco, California, United States, 94158
Contact: Mary Koestler    415-476-0661    mary.koestler@ucsf.edu   
Principal Investigator: Adam Boxer, MD         
United States, Maryland
Johns Hopkins Bayview Medical Center Recruiting
Baltimore, Maryland, United States, 21224
Contact: Toni White, MS    410-550-6486    twhite46@jhmi.edu   
Principal Investigator: Chiadi U Onyike, MD         
United States, New York
Columbia University Medical Center Completed
New York, New York, United States, 10032
United States, Washington
University of Washington Recruiting
Seattle, Washington, United States, 98195
Contact: Alicia Adams    206-221-9038    adamsali@uw.edu   
Principal Investigator: Kimiko Domoto-Reilly, MD         
Canada, British Columbia
University of British Columbia Completed
Vancouver, British Columbia, Canada
Canada, Ontario
Parkwood Institute Recruiting
London, Ontario, Canada, N6C 0A7
Contact: S Jesso, BA    519-646-6000    cognitiveneurology@sjhc.london.on.ca   
Principal Investigator: Elizabeth Finger, MD         
Sunnybrook Health Sciences Centre Completed
Toronto, Ontario, Canada
University Health Network Recruiting
Toronto, Ontario, Canada
Contact: Daniela Mora-Fisher    (416) 603-5800    daniela.mora-fisher@uhn.ca   
Principal Investigator: Carmela Tartaglia, MD         
Canada, Quebec
Montreal Neurological Institute and Hospital Recruiting
Montreal, Quebec, Canada
Contact: Michal Friedman    (514) 398-5750    michal.friedman@mcgill.ca   
Principal Investigator: Simon Ducharme, MD         
Laval University Recruiting
Quebec, Canada, G1J1Z4
Contact: Megane Lacombe-Thibault    418-649-0252    megane.lacombe-thibault@crchudequebec.ulaval.ca   
Principal Investigator: Robert LaForce, MD         
Sponsors and Collaborators
Lawson Health Research Institute
Weston Brain Institute
Canadian Institutes of Health Research (CIHR)
Berry Consultants
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT03260920    
Other Study ID Numbers: FTDOXY17EF
First Posted: August 24, 2017    Key Record Dates
Last Update Posted: January 17, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lawson Health Research Institute:
frontotemporal dementia
Additional relevant MeSH terms:
Layout table for MeSH terms
Frontotemporal Dementia
Pick Disease of the Brain
Frontotemporal Lobar Degeneration
Aphasia, Primary Progressive
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Neurodegenerative Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Reproductive Control Agents
Physiological Effects of Drugs